Biocon shares upgraded by Kotak Institutional Equities after recent correction improves risk-reward

What happened

Kotak Institutional Equities upgraded Biocon to “Add” from its previous rating and set a ₹390 price target, implying about 13% upside from Wednesday’s close. The call followed a weaker-than-expected September quarter, which Kotak attributed to deferred biosimilar shipments and slower generics growth.

Confirmed

Global impact / market context

The upgrade rests on expected growth in biosimilars and debt reduction, not on strong recent results. If product launches and expanded insulin capacity lift sales as forecast, higher revenue and operating efficiency could support earnings; delays would weaken that case.

Analyst inference

Biocon missed analyst estimates in the September quarter, while Kotak expects a stronger second half and forecasts annual growth in biosimilar revenue and EBITDA over the next several years. These are brokerage expectations, not reported results, so delivery depends on shipments, product growth and efficiency.

Analyst inference

What to watch

1. Whether delayed biosimilar shipments are delivered and the expected second-half strength materializes, since shipment timing directly affects how much sales Biocon reports in that period. Analyst inference
2. Whether new biosimilar launches and insulin capacity expansion translate into sales growth, as Kotak expects biosimilar revenue to grow annually over the coming years. Analyst inference
3. Whether debt reduction and improved operating efficiency support Kotak’s earnings forecast; EBITDA means earnings before interest, taxes, depreciation and amortization, and reflects operating performance. Analyst inference

Evidence

• Original source link unavailable